International Journal of Radiation Oncology*Biology*Physics
Original contributionRadiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia
References (31)
Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy
Radiother. Oncol.
(1985)- et al.
Misonidazole retention by normal tissues: A distinction between label on the ring and side chain
Int. J. Radiat. Onc. Biol. Phys.
(1986) - et al.
Binding of misonidazole to V79 spheroids and fragments of Dunning rat prostatic and human colon carcinomas in vitro: diffusion of O2 and reactive metabolites
Int. J. Radiat. Oncol. Biol. Phys.
(1984) - et al.
Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy
Int. J. Radiat. Oncol. Biol. Phys.
(1988) Does hyperbaric oxygen have a future in radiation therapy?
Int. J. Radiat. Oncol. Biol. Phys.
(1981)- et al.
Changes in misonidazole binding with hypoxic fraction in mouse tumors
Int. J. Radiat. Oncol. Biol. Phys.
(1985) - et al.
Applicability of animal tumors to cancer therapy in humans
Int. J. Radiat. Oncol. Biol. Phys.
(1988) - et al.
Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data
Int. J. Radiat. Oncol. Biol. Phys.
(1984) - et al.
Response of mouse skin and the C3HBA mammary carcinoma of the C3H mouse to X rays and cyclotron neutrons: effect of mixed neutron-photon fractionation schemes
Eur. J. Cancer
(1975) - et al.
Keynote addressthe problem: Tumor adioresistence in clinical radiotherapy
Int. J. Radiat. Oncol. Biol. Phys.
(1982)
The synthesis of tritium-labeled misonidazole
J. Labeled Comp. Radiopharmaceit.
Quantitative measurements of oxygen tension in normal tissues and in the tumours of patients before and after radiotherapy
Acta Radiol.
Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells
Cancer Res.
Marker for hypoxic cells in tumors with potential clinical applicability
Br. J. Cancer
Oxygen dependence of binding of misonidazole to rodent and human tumors in vitro
Cancer Res.
Cited by (179)
PET Imaging in Cancer Clinical Trials
2021, Molecular Imaging: Principles and PracticeImaging of Tumor Hypoxia for Radiotherapy: Current Status and Future Directions
2020, Seminars in Nuclear MedicineCitation Excerpt :Especially, 18F labeled 2-nitroimidazoles like FMISO are of interest since they are selectively trapped in viable hypoxic cells, as accumulation involves covalent binding to macromolecules after an oxygenation-dependent enzymatic reduction of the 2-nitro group. A second advantage is the tracer binding range, that increases steeply below 10 mmHg and reaches half-maximum at a pO2 of ∼1-2 mmHg101 (Busk et al, unpublished results), which is not very different from oxygenation-dependent radiosensitization, where half-maximum and full sensitization occurs roughly at 3 and 20 mmHg, respectively.102 Some correlation between overall tumor response to radiotherapy and hypoxia PET derived image metrics is therefore expected, whereas more accurate predictions of intratumor heterogeneity in radiosensitivity is more challenging.
Novel multifunctional <sup>18</sup>F-labelled PET tracer with prostate-specific membrane antigen-targeting and hypoxia-sensitive moieties
2020, European Journal of Medicinal Chemistry